BOLD (Boundless Bio) Days Payable : 0.00 (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio Days Payable?

Boundless Bio's average Accounts Payable for the three months ended in Sep. 2024 was $2.11 Mil. Boundless Bio's Cost of Goods Sold for the three months ended in Sep. 2024 was $0.00 Mil.

The historical rank and industry rank for Boundless Bio's Days Payable or its related term are showing as below:

BOLD's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 127.14
* Ranked among companies with meaningful Days Payable only.

Boundless Bio's Days Payable stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00). stayed the same

Boundless Bio Days Payable Historical Data

The historical data trend for Boundless Bio's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio Days Payable Chart

Boundless Bio Annual Data

Trend

Dec21

Dec22

Dec23

Days Payable

Boundless Bio Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Days Payable	Get a 7-Day Free Trial						-	-	-	-	-

Competitive Comparison of Boundless Bio's Days Payable

For the Biotechnology subindustry, Boundless Bio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Boundless Bio's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Boundless Bio's Days Payable distribution charts can be found below:

* The bar in red indicates where Boundless Bio's Days Payable falls into.

Boundless Bio Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Boundless Bio's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (1.402	+	2.222)	/	2 )	/	0	*	365
=	1.812					/	0	*	365
=	N/A

Boundless Bio's Days Payable for the quarter that ended in Sep. 2024 is calculated as:

	Days Payable (Q: Sep. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2024 )	+	Accounts Payable (Q: Sep. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
=	( (1.686	+	2.542)	/	2 )	/	0	*	365 / 4
=	2.114					/	0	*	365 / 4
=	N/A

Boundless Bio Days Payable Related Terms

Thank you for viewing the detailed overview of Boundless Bio's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Boundless Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

9880 Campus Point Drive, Suite 120, San Diego, CA, USA, 92121

Website

https://www.boundlessbio.com

Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.